Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003638723 | SCV001098544 | benign | Rubinstein-Taybi syndrome due to EP300 haploinsufficiency | 2025-01-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003259021 | SCV003945075 | likely benign | Inborn genetic diseases | 2023-03-31 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV004740515 | SCV005352876 | likely benign | EP300-related disorder | 2022-04-13 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |